Navigation Links
Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
Date:12/17/2009

NASDAQ: CRME TSX: COM

VANCOUVER, Dec. 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the recently-completed Phase 3 European Comparator Study (the AVRO study) evaluating vernakalant (iv) versus amiodarone for the acute conversion of atrial fibrillation met its primary endpoint.

The AVRO study achieved statistical significance in demonstrating the superiority of vernakalant (iv) over amiodarone in the conversion of atrial fibrillation to sinus rhythm within 90 minutes of the start of drug administration. Overall the data suggests that vernakalant (iv) was well-tolerated in the study population. There were no vernakalant-related deaths or cases of "Torsades de Pointes", a specific and well-characterized ventricular arrhythmia.

Cardiome expects that detailed results of this study will be presented at a scientific conference in 2010.

In April 2009, Cardiome and Merck & Co., Inc. announced a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides a Merck affiliate, Merck Sharp & Dohme Corp., with exclusive global rights to vernakalant (oral) for the maintenance of normal heart rhythm in patients with atrial fibrillation, and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to vernakalant (iv) for rapid conversion of acute atrial fibrillation to normal heart rhythm. If approved by the European regulatory authorities, Merck has exclusive rights to commercialize vernakalant (iv) in the European Union.

'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Release Third Quarter Results
2. Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial
3. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
4. Cardiome Pharma Corp. Announces Final Results of Tender Offer
5. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
6. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
7. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
8. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
9. Cardiome to Hold Conference Call
10. Cardiome Announces Management Transition
11. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... Le Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, ... the April issue of Nature Reviews Microbiology ... Dr. McCullers, a world-renowned infectious disease specialist, ... the University of Tennessee Health Science Center, analyzed ... 1918, 1957 and 1968 pandemics, as well as ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... University School of Medicine in St. Louis working with ... cells long thought to be responsible for type 1 ... immune cells from isolated insulin-making structures in the pancreas ... immune cells, known as dendritic cells, "red-handed": carrying insulin ...
... Retired Air Force,Colonel Mike Turner, a Democratic candidate for ... Care Countdown" inspired by MSNBC host,Keith Olbermann. Today is ... and a key architect of Hillary Clinton,s,notorious 1993 health ... to tell 10th District voters what, if any, plan ...
... Aid through Dubai Cares, DUBAI, United Arab Emirates, ... Maktoum, Vice President and Prime Minister of the,U.A.E. and ... structures to be used as schools and shelter to ... donation. The,official death toll currently stands at 22,000, with ...
... Calif., May 9 Dakim, Inc., announced,today that ... in,health and fitness, has signed on as a ... [m]Power Cognitive Fitness System, joining the,company,s efforts to ... is a touch screen-based brain workout program designed,to ...
... 9 Roche announced today that Sarah,Vidal, M.P.H., ... as a 2008 Rising Star by the Healthcare ... on May 8,2008 in New York City., ... combination of,confidence, energy, experience, contagious enthusiasm and respect ...
... to provide more visible presence for world,s largest surgical,organization, ... (ACS) today broke ground for a new home for ... presence on Capitol Hill. The,10-story, class A office building, ... the first quarter of 2010. ACS headquarters will remain ...
Cached Medicine News:Health News:Suspected cause of type 1 diabetes caught 'red-handed' for the first time 2Health News:Suspected cause of type 1 diabetes caught 'red-handed' for the first time 3Health News:Mike Turner, Virginia Congressional Candidate, Starts Healthcare Countdown 2Health News:Dubai Provides Aid for Cyclone Nargis Victims In Myanmar 2Health News:Physical Fitness 'Godfather' Jack LaLanne Turns to Brain Fitness, Becoming Ambassador for Dakim's [m]Power System 2Health News:Roche's Vidal Honored as 2008 HBA Rising Star 2Health News:American College of Surgeons Breaks Ground on New Office Building on Capitol Hill 2
(Date:1/15/2014)... DUBLIN , Jan. 15, 2014  Research and Markets ... "Dental Consumables Market - Global Industry Analysis, Size, ... report to their offering. (Logo: ... products which are used on patients in order to ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... - NEOPHARM, Inc.,(Nasdaq: NEOL) today reported findings ... metastatic colorectal cancer patients with its,drug product ... While the interim analysis of data following ... patients demonstrated,disease stabilization, the study did not ...
... OTCBB: CHKT, VANCOUVER, April 02, 2007 /PRNewswire-FirstCall/ ... biotechnology company,developing chemokine-based therapies to treat cancer, ... the,University of Texas M. D. Anderson Cancer ... metastasis with a CXCR4,antagonist in a mouse ...
Cached Medicine Technology:NeoPharm Provides Update on LE-SN38 Program 2M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 2M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 3M. D. Anderson Cancer Center Researchers to Present CTCE-9908 Data,at the AACR Annual Meeting 4
... The Signature Edition GOLD Infusion System ... customer input, as well as the ... Human factors design refers to the ... controls and displays engineered to reduce ...
... clinician documentation and electronic medical record (EMR) ... specific needs of intensive care units and ... clinical functionality has secured its place as ... critical care, and its the most reliable ...
... Electronic Health Record (EHR/EMR) ... (WfMS) Specialties that we ... Immunology, Cardiology, Dermatology, Family ... Neurology, Neurosurgery, Obstetrics and ...
... Clinic Pro Software developed a touchscreen EHR ... spring. While a user can choose to ... practitioner to maintain eye contact while recording ... Clinic Pro EHR also runs on a ...
Medicine Products: